Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India
Sponsor: Novo Nordisk A/S
Summary
This study will look at how safe is the medicine eptacog alfa when used in women in India for stopping heavy bleeding after giving birth. If participants have heavy bleeding after giving birth then they will get the medicine eptacog alfa. This study will be conducted to get more knowledge on the safety of the medicine eptacog alfa use in these women. At first participants will receive one dose of medicine eptacog alfa. If the given dose is not helpful to stop the bleeding, participants will get one additional dose. The study will last for about 30-35 days.
Official title: Safety of Eptacog Alfa in Severe Postpartum Haemorrhage in India: A Phase IV Interventional Study
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2025-08-26
Completion Date
2027-03-26
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
Eptacog alfa (NovoSeven)
Participants will receive single dose of intravenous bolus injection of eptacog alfa (NovoSeven)
Locations (8)
KLE Belgum
Belagavi, Karnataka, India
Calicut Medical College
Kozhikode, Kerala, India
Calicut Medical College
Kozhikode, Kerala, India
Seth GS Medical College & KEM Hospital
Mumbai, Maharashtra, India
All India Institute of Medical Sciences_New Dehli
New Delhi, National Capital Territory of Delhi, India
SMS Hospital
Jaipur, Rajasthan, India
KLE Belgum
Belagavi, India
Post Graduate Institute of Medical Education & Research_Chandigarh
Chandigarh, India